

11C-Acetate PET/CT

Verification of Patient Eligibility for Expanded Access IND

Patient Name:	Patient ID:
Gender:	Date of birth:
Referring Physician:	Ref Office Ph. #:

Indication for C-11Acetate PET/CT:

- Suspected clinical recurrence of prostate cancer after initial radiation or surgical treatment, with evidence of biochemical failure.
- Patient is treatment naive with respect to hormonal therapy.
- Patient is a candidate for salvage therapy or systemic therapy depending on the PET/CT C-11 acetate identified location and extent of recurrence.
- Hepatocellular carcinoma patient.
- Assessment of eligibility for liver transplant for patients meeting criteria.
- Evaluation of location and extent of disease for liver directed therapy inpatients who do not meet the Milan criteria.

Other relevant history:

Is a contrast enhanced CT scan indicated/needed, independent of the C-11 Acetate study? Yes No

Referring physician's clinical objectives for this diagnostic study?

**NOTE: The cost of production of the C-11 Acetate radiopharmaceutical is \$2,151. The patient will receive a bill for a negotiated amount of \$100.00, in addition to the technical charge for performance (\$12,210) and professional analysis (\$593) for the PET/CT scan. The referring physician will need to obtain pre authorization from the patient's insurance to cover these expenses, based on clinical need.*

****A physician's order is required with the submission of this eligibility form. Please submit forms to ORI Scheduling orisched@iu.edu or 317-274-8124.**

To be completed by Nuclear Medicine Physician:

Patient satisfies eligibility criteria of the Expanded Access IND: YES NO

NM Physician
Digital Signature

Please email to ORI Scheduling at
orisched@iu.edu